OCGN Ocugen, Inc.

7.41
+0.01  (+0%)
Previous Close 7.4
Open 7.32
52 Week Low 0.185
52 Week High 18.77
Market Cap $1,468,873,430
Shares 198,228,533
Float 192,970,788
Enterprise Value $1,261,185,461
Volume 34,537,855
Av. Daily Volume 78,877,188
Stock charts supplied by TradingView

Upcoming Catalysts

Drug Stage Catalyst Date
OCU400 (AAV-NR2E3)
Retinitis Pigmentosa
Phase 1/2
Phase 1/2
Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 14-day FREE TRIAL.

Drug Pipeline

Drug Stage Notes
COVAXIN
COVID-19 vaccine
Phase 3
Phase 3
Phase 3 interim data from partner Bharat Biotech noted efficacy rate of 78% - April 21, 2021. BLA filing to be submitted instead of FDA Emergency Use Authorization Application - June 10, 2021.
OCU 300
Graft Versus Host Disease
Phase 3
Phase 3
Phase 3 trial stopped early due to insufficient efficacy - June 1, 2020.

Latest News

  1. MALVERN, Pa., June 21, 2021 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ:OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, today announced that Ken Inchausti has joined the company as Head, Investor Relations & Communications. Mr. Inchausti will oversee the company's investor relations activities, corporate communications and strategic positioning, leading issues management strategy and proactive media and social media relations programming.

    A senior executive with over 25 years of strategic healthcare communications experience, Mr. Inchausti joins Ocugen from Novo Nordisk Inc., where he was Senior Director…

    MALVERN, Pa., June 21, 2021 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ:OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, today announced that Ken Inchausti has joined the company as Head, Investor Relations & Communications. Mr. Inchausti will oversee the company's investor relations activities, corporate communications and strategic positioning, leading issues management strategy and proactive media and social media relations programming.

    A senior executive with over 25 years of strategic healthcare communications experience, Mr. Inchausti joins Ocugen from Novo Nordisk Inc., where he was Senior Director, Reputation & Brand, leading corporate media relations, executive visibility, reputation strategy and research, crisis and issues management and corporate communications for the US affiliate.

    "Ken is joining us at a critical time where we are continuing our plans for obtaining regulatory approval for and potentially commercializing COVAXIN® in the US and Canada, as well as the planned initiation our Phase 1/2a clinical trial for OCU400. His talents and expertise will be key as we seek to find new ways of raising our profile with multiple stakeholders as a leader committed to global public health and fighting this pandemic, and also driving innovation through our gene therapy platform to find cures for leading causes of blindness," said Sanjay Subramanian, MBA, Chief Financial Officer and Head of Corporate Development at Ocugen, Inc.

    Mr. Inchausti has worked across multiple sectors within healthcare – from pharmaceuticals to hospitals and providers to patient advocacy. Prior to Novo Nordisk, he held communications positions at GSK, Premier, Inc., Fleishman Hillard, and the American Diabetes Association.

    Mr. Inchausti holds a bachelor's degree in Communications from Old Dominion University.

    About Ocugen, Inc.

    Ocugen, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19. Our breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with one drug — "one to many," and our novel biologic product candidate aims to offer better therapy to patients with underserved diseases such as wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy. We are co-developing Bharat Biotech's COVAXIN vaccine candidate for COVID-19 in the U.S. and Canadian markets. For more information, please visit www.ocugen.com.

    Cautionary Note on Forward-Looking Statements 

    This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties. Such forward-looking statements within this press release include, without limitation, the intended use of net proceeds from the registered direct offering. We may, in some cases, use terms such as "predicts," "believes," "potential," "proposed," "continue," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "will," "should" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from our current expectations, such as market and other conditions. These and other risks and uncertainties are more fully described in our periodic filings with the Securities and Exchange Commission (the "SEC"), including the risk factors described in the section entitled "Risk Factors" in the quarterly and annual reports that we file with the SEC. Any forward-looking statements that we make in this press release speak only as of the date of this press release. Except as required by law, we assume no obligation to update forward-looking statements contained in this press release whether as a result of new information, future events or otherwise, after the date of this press release.

    Ocugen Contact:

    Ocugen, Inc.

    Ken Inchausti

    Head, Investor Relations and Communications

    Please submit investor-related inquiries to:

    Media Contact:

    LaVoieHealthScience

    Lisa DeScenza



    +1 978-395-5970



    Primary Logo

    View Full Article Hide Full Article
  2. MALVERN, Pa., June 18, 2021 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ:OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, today announced the Compensation Committee of the Board of Directors of Ocugen approved the grant of stock options to purchase an aggregate of 157,450 shares of its common stock and restricted stock units (RSUs) covering an aggregate of 26,300 shares of common stock to four new employees. The stock options and RSUs were granted as of June 15, 2021, as material inducements to employment in accordance with Nasdaq Listing Rule 5635(c)(4).

    The stock options have a ten-year term and have an exercise…

    MALVERN, Pa., June 18, 2021 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ:OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, today announced the Compensation Committee of the Board of Directors of Ocugen approved the grant of stock options to purchase an aggregate of 157,450 shares of its common stock and restricted stock units (RSUs) covering an aggregate of 26,300 shares of common stock to four new employees. The stock options and RSUs were granted as of June 15, 2021, as material inducements to employment in accordance with Nasdaq Listing Rule 5635(c)(4).

    The stock options have a ten-year term and have an exercise price of $6.26 per share, which is the closing price of Ocugen's common stock on the grant date. The stock options and RSUs vest in equal annual installments over a three-year period starting on the one-year anniversary of the grant date, subject to the applicable new employee's continued service with Ocugen through the applicable vesting dates. The stock options and RSUs were granted outside of Ocugen's 2019 Equity Incentive Plan.

    About Ocugen, Inc.

    Ocugen, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19. Our breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with one drug — "one to many," and our novel biologic product candidate aims to offer better therapy to patients with underserved diseases such as wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy. We are co-developing Bharat Biotech's COVAXIN vaccine candidate for COVID-19 in the U.S. and Canadian markets. For more information, please visit www.ocugen.com.

    Cautionary Note on Forward-Looking Statements 

    This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties. Such forward-looking statements within this press release include, without limitation, the intended use of net proceeds from the registered direct offering. We may, in some cases, use terms such as "predicts," "believes," "potential," "proposed," "continue," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "will," "should" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from our current expectations, such as market and other conditions. These and other risks and uncertainties are more fully described in our periodic filings with the Securities and Exchange Commission (the "SEC"), including the risk factors described in the section entitled "Risk Factors" in the quarterly and annual reports that we file with the SEC. Any forward-looking statements that we make in this press release speak only as of the date of this press release. Except as required by law, we assume no obligation to update forward-looking statements contained in this press release whether as a result of new information, future events or otherwise, after the date of this press release. 

    Ocugen Contact: 

    Ken Inchausti

    Head, Investor Relations & Communications

     



    Primary Logo

    View Full Article Hide Full Article
  3. MALVERN, Pa., June 16, 2021 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ:OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, today announced that it is set to join the broad-market Russell 3000® Index at the conclusion of the 2021 Russell indexes annual reconstitution, effective after the US market opens on June 28, 2021, according to a preliminary list of additions posted June 4, 2021.

    The annual Russell indexes reconstitution captures the 4,000 largest US stocks as of May 7, 2021, ranking them by total market capitalization. Membership in the US all-cap Russell 3000® Index, which remains in place for one…

    MALVERN, Pa., June 16, 2021 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ:OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, today announced that it is set to join the broad-market Russell 3000® Index at the conclusion of the 2021 Russell indexes annual reconstitution, effective after the US market opens on June 28, 2021, according to a preliminary list of additions posted June 4, 2021.

    The annual Russell indexes reconstitution captures the 4,000 largest US stocks as of May 7, 2021, ranking them by total market capitalization. Membership in the US all-cap Russell 3000® Index, which remains in place for one year, means automatic inclusion in the large-cap Russell 1000® Index or small-cap Russell 2000® Index as well as the appropriate growth and value style indexes. FTSE Russell determines membership for its Russell indexes primarily by objective, market-capitalization rankings, and style attributes.

    "As part of the reconstitution process to ensure that new and growing equities are included, we are pleased to be added to the Russell 3000® index which measures the performance of the largest US companies representing approximately 98% of the investable US equity market," said Sanjay Subramanian, CFO and Head of Corporate Development of Ocugen.

    Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. Approximately $10.6 trillion in assets are benchmarked against Russell's US indexes. Russell indexes are part of FTSE Russell, a leading global index provider.

    For more information on the Russell 3000® Index and the Russell indexes reconstitution, go to the "Russell Reconstitution" section on the FTSE Russell website.

    About Ocugen, Inc.

    Ocugen, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19. Our breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with one drug – "one to many" and our novel biologic product candidate aims to offer better therapy to patients with underserved diseases such as wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy. We are co-developing Bharat Biotech's COVAXIN™ vaccine candidate for COVID-19 in the US and Canadian markets. For more information, please visit http://ocugen.com/

    About FTSE Russell

    FTSE Russell is a global index leader that provides innovative benchmarking, analytics, and data solutions for investors worldwide. FTSE Russell calculates thousands of indexes that measure and benchmark markets and asset classes in more than 70 countries, covering 98% of the investable market globally.

    FTSE Russell index expertise and products are used extensively by institutional and retail investors globally. Approximately $17.9 trillion is currently benchmarked to FTSE Russell indexes. For over 30 years, leading asset owners, asset managers, ETF providers and investment banks have chosen FTSE Russell indexes to benchmark their investment performance and create ETFs, structured products and index-based derivatives.

    A core set of universal principles guides FTSE Russell index design and management: a transparent rules-based methodology is informed by independent committees of leading market participants. FTSE Russell is focused on applying the highest industry standards in index design and governance and embraces the IOSCO Principles. FTSE Russell is also focused on index innovation and customer partnerships as it seeks to enhance the breadth, depth and reach of its offering.

    FTSE Russell is wholly owned by London Stock Exchange Group. For more information, visit https://www.ftserussell.com/.

    Cautionary Note on Forward-Looking Statements

    This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties. Such forward-looking statements within this press release include, without limitation, the intended use of net proceeds from the registered direct offering. We may, in some cases, use terms such as "predicts," "believes," "potential," "proposed," "continue," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "will," "should" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from our current expectations, such as market and other conditions. These and other risks and uncertainties are more fully described in our periodic filings with the Securities and Exchange Commission (the "SEC"), including the risk factors described in the section entitled "Risk Factors" in the quarterly and annual reports that we file with the SEC. Any forward-looking statements that we make in this press release speak only as of the date of this press release. Except as required by law, we assume no obligation to update forward-looking statements contained in this press release whether as a result of new information, future events or otherwise, after the date of this press release.

    Ocugen Contact:

    Ocugen, Inc.

    Sanjay Subramanian

    Chief Financial Officer and Head of Corp. Dev.

    Media Contact:

    LaVoieHealthScience

    Lisa DeScenza



    +1 978-395-5970



    Primary Logo

    View Full Article Hide Full Article
  4. MALVERN, Pa., June 15, 2021 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ:OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, today announced that it has selected Jubilant HollisterStier of Spokane, Washington as its manufacturing partner for COVAXIN™ to prepare for potential commercial manufacturing of COVAXIN™ for the US and Canadian markets.

    "We are fully committed to bringing COVAXIN to the US and Canadian markets because we believe it has the potential to save lives by adding a weapon to the arsenal in the fight against emerging variants," said J.P. Gabriel, Ocugen's Senior Vice President, Manufacturing and…

    MALVERN, Pa., June 15, 2021 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ:OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, today announced that it has selected Jubilant HollisterStier of Spokane, Washington as its manufacturing partner for COVAXIN™ to prepare for potential commercial manufacturing of COVAXIN™ for the US and Canadian markets.

    "We are fully committed to bringing COVAXIN to the US and Canadian markets because we believe it has the potential to save lives by adding a weapon to the arsenal in the fight against emerging variants," said J.P. Gabriel, Ocugen's Senior Vice President, Manufacturing and Supply Chain. "Securing US-based manufacturing capability is a critical step as we prepare to submit our regulatory submissions to the FDA and Health Canada. Based on Bharat Biotech's strong track record of developing and commercializing vaccines globally and Jubilant's proven track record in manufacturing, we are well-prepared to transition US manufacturing of COVAXIN to our new partner."

    "We are excited to expand our basket of vaccine products and meet the increasing demand from our customers for COVID-19 vaccines in the US," said Amit Arora, President Jubilant HollisterStier.

    "We are pleased to partner with Ocugen and support the ongoing fight against COVID-19. With two facilities in North America working to manufacture multiple COVID-19 vaccines and therapies, we remain committed to supporting efforts to eradicate this global pandemic," stated Pramod Yadav, CEO Jubilant Pharma Limited.

    About COVAXIN™

    COVAXIN™, India's COVID-19 vaccine by Bharat Biotech, is developed in collaboration with the Indian Council of Medical Research (ICMR) - National Institute of Virology (NIV). COVAXIN™ is a highly purified and inactivated vaccine that is manufactured using a vero cell manufacturing platform. This platform has an excellent safety track record of more than 300 million doses of various vaccines supplied. Based on a traditional vaccine platform that has a long-established safety profile, COVAXIN™ continues to show strong results in all the studies conducted to date including a vaccine efficacy rate of 78% overall efficacy and 100% in severe COVID-19 disease, including hospitalizations, in second interim results of Bharat Biotech's Phase 3 clinical trial.

    In addition to generating strong immune response against multiple antigens, COVAXIN has been shown to generate memory T cell responses, for its multiple epitopes, indicating longevity and a rapid antibody response to future infections. With published data demonstrating a safety profile superior to published safety data from separate studies for several other vaccines, COVAXIN is packaged in multi-dose vials that can be stored at 2-8⁰C.

    COVAXIN studies show potential effectiveness against three key variants of SARS-CoV-2. Scientists at the Indian Council of Medical Research (ICMR)-National Institute of Virology, using an in-vitro plaque reduction neutralization assay, have found that COVAXIN-vaccinated sera effectively neutralized the Brazil variant of SARS-CoV-2, B.1.128.2, the alpha variant, B.1.1.7, which was first identified in the United Kingdom, as well as the delta variant, B.1.617, which was first identified in India. These studies suggest that COVAXIN vaccination may be effective against multiple SARS-CoV-2 variants.

    Based on the more than 30 million doses supplied in India and other countries, COVAXIN has an excellent safety record. COVAXIN is currently being administered under emergency use authorizations in 13 countries, and applications for emergency use authorization are pending in more than 60 additional countries.

    About Ocugen, Inc.

    Ocugen, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19. Our breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with one drug – "one to many" and our novel biologic product candidate aims to offer better therapy to patients with underserved diseases such as wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy. We are co-developing Bharat Biotech's COVAXIN™ vaccine candidate for COVID-19 in the U.S. and Canadian markets. For more information, please visit www.ocugen.com.

    About Jubilant HollisterStier

    Jubilant HollisterStier, a part of Jubilant Pharma Limited, is a leading integrated contract manufacturer of sterile injectables, ophthalmics, otics, sterile and non-sterile topicals and liquids. With facilities in North America, Jubilant HollisterStier provides specialized manufacturing for the pharmaceutical and biopharmaceutical industries. Services include a full-range of support to streamline the manufacturing process, from process qualifications through commercial release.

    About Jubilant Pharma Limited

    Jubilant Pharma Limited (JPL), a company incorporated under the laws of Singapore and a wholly-owned subsidiary of Jubilant Pharmova Limited, is an integrated global pharmaceutical company engaged in manufacturing and supply of APIs, Solid Dosage Formulations, Radiopharmaceuticals, Allergy Therapy Products and Contract Manufacturing of Sterile Injectables and Non Sterile products through six US FDA approved manufacturing facilities in the US, Canada and India and a network of 48 radiopharmacies in the US. The Company has a team of around 5,200 multicultural people across the globe and is committed to deliver value to its customers spread across over 75 countries. It is well recognized as a 'Partner of Choice' by leading pharmaceutical companies globally.

    Cautionary Note on Forward-Looking Statements

    This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties. We may, in some cases, use terms such as "predicts," "believes," "potential," "proposed," "continue," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "will," "should" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such forward-looking statements include information about qualitative assessments of available data, potential benefits, expectations for clinical trials, and anticipated timing of clinical trial readouts and regulatory submissions. This information involves risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as risks associated with preliminary and interim data (including the interim data from Bharat Biotech's Phase 3 trial in India), including the possibility of unfavorable new clinical trial data and further analyses of existing clinical trial data; the risk that the results of in-vitro studies will not be duplicated in human clinical trials; the risk that clinical trial data are subject to differing interpretations and assessments, including during the peer review/publication process, in the scientific community generally, and by regulatory authorities; whether and when data from Bharat Biotech's clinical trials will be published in scientific journal publications and, if so, when and with what modifications; whether we will be able to provide the U.S. Food and Drug Administration (FDA) with sufficient additional information regarding the design of and results from preclinical and clinical studies of COVAXIN, which have been conducted by Bharat Biotech in India in order for those trials to support a biologics license application (BLA), the size, scope, timing and outcome of any additional trials or studies that we may be required to conduct to support a BLA; any additional chemistry, manufacturing and controls information that we may be required to submit the timing of our BLA filing; whether and when an application for authorization under interim order for emergency use will be filed in Canada; whether and when any such applications may be approved by Health Canada; whether developments with respect to COVID-19 pandemic will affect the regulatory pathway available for vaccines in the United States, Canada or other jurisdictions; market demand for COVAXIN in the United States or Canada; decisions by the FDA or Health Canada impacting labeling, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of COVAXIN in the United States or Canada, including development of products or therapies by other companies. These and other risks and uncertainties are more fully described in our periodic filings with the Securities and Exchange Commission (SEC), including the risk factors described in the section entitled "Risk Factors" in the quarterly and annual reports that we file with the SEC. Any forward-looking statements that we make in this press release speak only as of the date of this press release. Except as required by law, we assume no obligation to update forward-looking statements contained in this press release whether as a result of new information, future events or otherwise, after the date of this press release.

    Ocugen Contact:

    Ocugen, Inc.

    Sanjay Subramanian

    CFO and Head of Corp. Dev.

     

    Media Contact:

    LaVoieHealthScience

    Lisa DeScenza

     

    +1 9783955970



    Primary Logo

    View Full Article Hide Full Article
  5. SIOUX FALLS, S.D., June 10, 2021 /PRNewswire-PRWeb/ -- MarketBeat, the leading source for stock market data and research tools, has published its list of "The 10 Most Searched Stocks on MarketBeat in May 2021".

    Rankings are calculated based on the number of new MarketBeat users that have added the stock to their watchlist in May and the number of search queries for a company on MarketBeat in the same timeframe. While the monthly report is accessible to all users, MarketBeat All-Access subscribers can use the Trending Stocks Report to identify such companies based on the actions and interests of MarketBeat readers and subscribers.

    "Targeting trending stocks is a proven strategy for both individual and institutional investors, which is why our…

    SIOUX FALLS, S.D., June 10, 2021 /PRNewswire-PRWeb/ -- MarketBeat, the leading source for stock market data and research tools, has published its list of "The 10 Most Searched Stocks on MarketBeat in May 2021".

    Rankings are calculated based on the number of new MarketBeat users that have added the stock to their watchlist in May and the number of search queries for a company on MarketBeat in the same timeframe. While the monthly report is accessible to all users, MarketBeat All-Access subscribers can use the Trending Stocks Report to identify such companies based on the actions and interests of MarketBeat readers and subscribers.

    "Targeting trending stocks is a proven strategy for both individual and institutional investors, which is why our Trending Stocks Report remains a trusted and popular tool among our subscribers," said MarketBeat founder and CEO Matt Paulson. "While we maintain the most accurate picture of the investment marketplace by providing up-to-the-minute real-time data, this monthly ranking captures a snapshot of the market's top movers."

    MarketBeat offers the world's most comprehensive set of company profile data for publicly traded companies in the U.S. and tracks approximately 162,000 analyst recommendations from equities analysts in the U.S., U.K., and Canada annually.

    The Top Ten Most Searched Stocks on MarketBeat in May 2021 are:

    1. AMC Entertainment (NYSE:AMC) – Investors can't get enough of AMC stock. However, unlike when the stock popped as part of meme stock mania, this time investors may have a case.

    2. Apple (NASDAQ:AAPL) - Apple continues to impress investors with strong growth, but analysts may be wondering if all that growth is priced into AAPL stock.

    3. Palantir Technologies (NYSE:PLTR) – Investors are getting their head around the possibilities of the company's distinct programs for public and private sector clients, making it likely that PLTR stock will be on this list for months to come.

    4. Tesla (NASDAQ:TSLA) – Tesla remains one of the most actively traded stocks and with good reason. TSLA stock is up 241% in the trailing twelve months ending June 2, 2001.

    5. Nio (NYSE:NIO) – The "Tesla of China" continues to impress investors with strong delivery numbers. And until there is a clear winner in the race to build a better battery, Nio's battery-as-a-service (BaaS) program gives the company a distinct advantage.

    6. Microsoft (NASDAQ:MSFT) – MSFT stock is down in the last 30 days, but that just looks like a buy-the-dip opportunity. Fresh off the launch of a new Xbox gaming console in November 2020, Microsoft will launch the latest version of Windows on June 24, 2021.

    7. Ocugen (NASDAQ:OCGN) – This small biotech briefly surged on news that it is attempting to get a Covid-19 vaccine candidate, Covaxin, approved for use in the United States.

    8. Ford (NYSE:F) - For long-suffering Ford investors, the phrase "it's about time" comes to mind. Ford was at the tip of the spear when it came to being all-in on electrification.

    9. Tilray (NYSE:TLRY) – Tilray is now the largest cannabis producer, and TLRY stock is getting a lift after completing its merger with Aphria.

    10. Amazon (NASDAQ:AMZN) – Like Apple, AMZN stock has been trading sideways despite the fact that the tech giant continues to post strong growth numbers. A new CEO along with its recent absorption of MGM Films will be among the many things that will keep the stock top of mind for many investors.

    Find the full report at marketbeat.com.

    About MarketBeat

    MarketBeat is a financial media company based in Sioux Falls, South Dakota. MarketBeat's mission is to empower individual investors to make better trading decisions by providing real-time financial information and objective market research. More than 2.3 million investors receive MarketBeat's flagship newsletter, MarketBeat Daily Ratings. MarketBeat also publishes a network of financial news websites that garner more than 25 million pageviews each month, a suite of web-based investment research software called MarketBeat All Access, and a mobile stock research app on iOS and Android. For more information, visit marketbeat.com.

    Media Contact

    Ngoc Thach, MarketBeat, +1 (605) 940-8824,

     

     

    SOURCE MarketBeat

    View Full Article Hide Full Article
View All Ocugen, Inc. News